Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Gemcitabine and Cisplatin in NPC with Residual EBV DNA
NCT00370890Phase 3Completed
- Sponsor
- The Chinese University of Hong Kong
- Start
- Sep 2006
- Primary completion
- Oct 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemcitabine, Cisplatin micelle injection (HA132) in nasopharyngeal carcinoma (NPC), sponsored by The Chinese University of Hong Kong. Started Sep 2006; status: completed.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT00370890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00370890.